Search Results
Part 1 in a Series of Reports on Blatant, Widespread Stock Manipulation that is Enabled by Illegal, Naked Shorting
Stock Manipulation by Short Sellers is Endemic on Wall Street I am convinced that price manipulation by Wall Street bad actors is endemic in the capital markets and swindles legitimate investors out of billions of dollars each year. This criminal enterprise is particularly directed against the stocks of emerging growth companies that are at the […]
Illegal Naked Short Selling Appears to Lie at the Heart of an Extensive Stock Manipulation Scheme
Investment Consequences of Naked Shorting Only a motivated enforcement agency with subpoena power and an accompanying powerful enforcement infrastructure can prove that naked shorting is at the heart of an extensive stock manipulation scheme. However, I believe that the observational evidence is overwhelming that naked shorting practices are widely used to manipulate the stock prices […]
Denial of the Motion to Dismiss in Northwest Biotherapeutics Lawsuit Against Seven Wall Street Market Makers for Spoofing Would be a Major Catalyst for the Company
Key Points: I believe that the lawsuit will be allowed to go to discovery before or around mid-year. This will allow access to the trading records and computer algorithms used by market makers to spoof NWBO’s stock. This information will dramatically illustrate that Northwest has been the subject of a decade long stock manipulation scheme […]
Highly Probable UK Approval of DCVax-L in 3Q, 2024 Would Be a Crowning Achievement for Northwest Biotherapeutics
Key Points: On December 21, 2023, NWBO announced that it had submitted its MAA seeking regulatory approval for DCVax-L in the UK. The Company requested that MHRA review DCVax-L using the accelerated pathway and, in this report, I go over the reasons why I think the MHRA will do so. (The section in this report […]
Northwest Biotherapeutics: Comments on FDA Guidance for Use of Contemporaneous External Controls; Importance for DCVax-L
The FDA just issued new guidance on the use of contemporaneous external controls in clinical trials. Hedge funds who are massively short Northwest Biotherapeutics stock have falsely argued that the FDA cannot and will not accept contemporaneous external controls as used in the phase 3 DCVax-L clinical trial in glioblastoma. It is their fervent hope […]
Why I Believe Northwest Biotherapeutics Has Been and Continues to be the Subject of a Powerful Stock Manipulation Scheme
DCVax-L Impressive Phase 3 Results Are Validated by Independent, Expert Scientists and Physicians; Supports Strong Upward Stock Move The final results of the phase 3 trial of DCVax-L were first released on May 10 at the New York Academy of Sciences conference. They were extremely encouraging showing that glioblastoma (GBM) patients treated with DCVax-L plus […]
Northwest Biotherapeutics’ Day Has Come at Last
I’m Back Earlier this year I decided to end subscriptions to SmithOnStocks.com. Researching and writing articles on biotechnology companies required a significant amount of time and effort that detracted from other things that I wanted to do. I am very curious by nature and get genuinely excited when learning new things. My interests include biology, […]
Northwest Biotherapeutics: Debunking Silly, Fictitious Adam Feuerstein Article Falsely Claiming Phase 3 Trial of DCVax-L in Glioblastoma Multiforme Was a Failure
Introduction I am really outraged. The long awaited phase 3 results for DCVax-L in newly diagnosed and recurrent glioblastoma multiforme were a stunning success. The data was peer reviewed and presented at the prestigious New York Academy of Sciences on May 10, 2022. I discuss the data at length in this report and I am […]
Presentation at the New York Academy of Sciences on Final Results of Phase 3 DCVax-L Trial Showing Impressive Efficacy (Part 3) Analyzing Hedge Fund Stock Manipulation Techniques
Introduction This note describes why I believe that the sharp downward price movement yesterday resulted from stock manipulation by a group of hedge funds that I call the wolfpack. It was a bold and frightening effort to make investors fear that the very positive news from the presentation at the academy was actually negative, In […]
Presentation at the New York Academy of Sciences on Final Results of Phase 3 DCVax-L Trial Showing Impressive Efficacy (Part 1) Debunking Hedge Fund Misinformation
Overview The much anticipated presentation at the New York Academy of Sciences of final results of the phase 3 trial of DCVax-L in newly diagnosed and recurrent glioblastoma was just completed. Investigators in the trial as well as questioners in the audience not affiliated with the trial described DCVax-L as a major advance in the […]